Gilteritinib vs Quizartinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Acute Myeloid Leukemia

Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline

Gilteritinib

Marketed by Astellas Pharma

Approved in Acute Myeloid Leukemiasmall molecule
Partial signal

NCT02997202 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial with 178 participants per group and a hard clinical primary endpoint of relapse-free survival. The primary endpoint was not statistically significant (hazard ratio 0.679; p=0.0518), so the results provide well-controlled but inconclusive evidence of benefit.

Next expected readout: December 2026 · NCT06001788 (registry estimate)

Reported efficacy

Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) (missed)

Result source: NCT02752035

Quizartinib

Marketed by Daiichi Sankyo and partners

Approved in Acute Myeloid Leukemiasmall molecule
Reliable signal

NCT02668653 · Phase 3 · completed

The trial randomized 539 participants to quizartinib plus chemotherapy or placebo plus chemotherapy, with participants, investigators, and outcome assessors masked. Its hard primary endpoint, overall survival, was met in favor of quizartinib, with a statistically significant hazard ratio of 0.776 (p=0.0324).

Next expected readout: May 2027 · NCT03793478 (registry estimate)

Reported efficacy

Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) (met)

Result source: NCT02668653

Results for Acute Myeloid Leukemia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGilteritinibQuizartinib
OS, median9.8 vs 9.2vs AZAn 89NCT02752035
3 other results
31.9 vs 15.1+16.8 vs placebon 268NCT02668653
8 other results
Complete remission21.1% vs 10.5%vs Salvage Chemotherapywk 24 · n 247NCT02421939
4 other results
  • 25.8% vs 17.5% n 89 · Phase 3 · secondary NCT02752035
  • 9.1% vs 17.5% n 22 · Phase 3 · secondary NCT02752035
  • 33.3% 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 0% 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
2.6%b60 mg · wk 156 · n 38NCT01565668
1 other result
  • 5.3% 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
Event-free survival, median0.0 vs 0.0vs AZAn 89NCT02752035
5 other results
  • 2.8 vs 0.7 n 189 · Phase 3 · secondary NCT02421939
  • 0.0 vs 0.0 n 22 · Phase 3 · secondary NCT02752035
  • 14.1 vs 6.7 n 63 · Phase 2 · secondary NCT02927262
  • 5.8 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 1.7 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
0.0 vs 0.7−0.7 vs placebon 268NCT02668653
5 other results
  • 1.4 vs 0.8 wk 195 · n 245 · Phase 3 · secondary NCT02039726
  • 3.2 60 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.8 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.9 30 mg/day · n 29 · Phase 2 · secondary NCT02984995
  • 0.0 20 mg/day · n 3 · Phase 2 · secondary NCT02984995
Duration of response, median14.8 vs 1.8vs Salvage Chemotherapyn 52NCT024219393.6bn 83NCT00989261
3 other results

OS, median

Gilteritinib
9.8 vs 9.2vs AZAn 89NCT02752035
3 other results
Quizartinib
31.9 vs 15.1+16.8 vs placebon 268NCT02668653
8 other results

Complete remission

Gilteritinib
21.1% vs 10.5%vs Salvage Chemotherapywk 24 · n 247NCT02421939
4 other results
  • 25.8% vs 17.5% n 89 · Phase 3 · secondary NCT02752035
  • 9.1% vs 17.5% n 22 · Phase 3 · secondary NCT02752035
  • 33.3% 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 0% 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
Quizartinib
2.6%b60 mg · wk 156 · n 38NCT01565668
1 other result
  • 5.3% 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668

Event-free survival, median

Gilteritinib
0.0 vs 0.0vs AZAn 89NCT02752035
5 other results
  • 2.8 vs 0.7 n 189 · Phase 3 · secondary NCT02421939
  • 0.0 vs 0.0 n 22 · Phase 3 · secondary NCT02752035
  • 14.1 vs 6.7 n 63 · Phase 2 · secondary NCT02927262
  • 5.8 120 mg + 420 mg · n 3 · Phase 1/2 · secondary NCT03730012
  • 1.7 120 mg + 840 mg · n 8 · Phase 1/2 · secondary NCT03730012
Quizartinib
0.0 vs 0.7−0.7 vs placebon 268NCT02668653
5 other results
  • 1.4 vs 0.8 wk 195 · n 245 · Phase 3 · secondary NCT02039726
  • 3.2 60 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.8 30 mg · wk 156 · n 38 · Phase 2 · secondary NCT01565668
  • 2.9 30 mg/day · n 29 · Phase 2 · secondary NCT02984995
  • 0.0 20 mg/day · n 3 · Phase 2 · secondary NCT02984995

Duration of response, median

Gilteritinib
14.8 vs 1.8vs Salvage Chemotherapyn 52NCT02421939
Quizartinib
3.6bn 83NCT00989261
3 other results
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. Gilteritinib: 9 of 9 rows · Quizartinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricGilteritinib
Rows use multiple source trials
Quizartinib
Rows use multiple source trials
Complete Remission
responder rate · % of participants
No placebo or comparator arm
33.3% (n=3)120 mg + 420 mga,b,c,d,e
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
0% (n=8)120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
2.6% (n=38) @ 156wk*60 mga,b,c,d,e
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted
show 1 more dose
5.3% (n=38) @ 156wk*30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted
CRc
responder rate · % of participants
No placebo or comparator arm
33.3% (n=3)120 mg + 420 mga,b,f,d,e
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
12.5% (n=8)120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
56.5% (n=23)30 mg/daya,b,f,d,e
NCT02984995 · Phase 2 · registry result, not featured evidence
show 1 more dose
33.3% (n=3)20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
Duration of Response
time to event · months
No placebo or comparator arm
NA months120 mg + 420 mga,b,f,d,e
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
NA months120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
3.62 months*a,b,f,d,e
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 15.7 weeks as posted
show 3 more doses
5.17 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 22.4 weeks as posted
3.25 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 14.1 weeks as posted
1.87 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 8.1 weeks as posted
Event Free Survival
time to event · months
No placebo or comparator arm
5.75 months*120 mg + 420 mga,b,f,d,e
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 175 days as posted
show 1 more dose
1.72 months*120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 52.5 days as posted
2.93 months*30 mg/daya,b,f,d,e
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 12.7 weeks as posted
show 1 more dose
0.02 months*20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 0.1 weeks as posted
Overall Survival
time to event · months
No placebo or comparator arm
NA months120 mg + 420 mga,b,f,d,e
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
show 1 more dose
5.75 months*120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 175 days as posted
7.87 months*30 mg/daya,b,f,d,e
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 34.1 weeks as posted
show 1 more dose
NA months20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
Dropout rate
31.5%g
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
—Randomized Cohort: Gilteritinib
NCT02752035 · Phase 3 · monotherapy
—Randomized Cohort: Gilteritinib +
NCT02752035 · Phase 3 · combination
n/a: no completion milestoneSafety Cohort: Gilteritinib + Azac
NCT02752035 · Phase 3 · combination
100%
NCT02421939 · Phase 3
61.9%
NCT02927262 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone120 mg + 420 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
100%200 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
100%120 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
66.7%80 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
100%40 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
n/a: no completion milestone20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
79.1%g
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
18.4%
NCT02039726 · Phase 3 · registry result, not featured evidence
73.5%30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
—20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
100%20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone60 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
9.6%Cohort 1; ≥60 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
12.5%Cohort 2; ≥18 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
0%Phase 1 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 2 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 2 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
66.7%40 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
50%20 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
100%60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
16.7%60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
0%40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
20%40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
0%25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 1
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—450 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—135 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—90 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—60 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—40 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—27 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—18 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—12 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—g
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
—Randomized Cohort: Gilteritinib
NCT02752035 · Phase 3 · monotherapy
—Randomized Cohort: Gilteritinib +
NCT02752035 · Phase 3 · combination
6.7%Safety Cohort: Gilteritinib + Azac
NCT02752035 · Phase 3 · combination
13%
NCT02421939 · Phase 3
11.1%
NCT02927262 · Phase 2 · registry result, not featured evidence
0%120 mg + 420 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
12.5%120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
—200 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
—450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
17.6%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
25%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
20.6%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
7.2%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
9.5%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
13.3%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
0%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
21.6%g
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
—
NCT02039726 · Phase 3 · registry result, not featured evidence
2.9%30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
—20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
0%20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
2.6%60 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
15.8%30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
—Cohort 1; ≥60 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
—Cohort 2; ≥18 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
—Phase 1 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
—40 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
—20 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—ALL Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 1
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
—AML Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
—450 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—300 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
—200 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—135 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—90 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—60 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—40 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—27 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—18 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
—12 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
Serious AEs
51.7%g
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
90.9%Randomized Cohort: Gilteritinib
NCT02752035 · Phase 3 · monotherapy
92%Randomized Cohort: Gilteritinib +
NCT02752035 · Phase 3 · combination
93.3%Safety Cohort: Gilteritinib + Azac
NCT02752035 · Phase 3 · combination
85.8%
NCT02421939 · Phase 3
38.7%
NCT02927262 · Phase 2 · registry result, not featured evidence
100%120 mg + 420 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
87.5%120 mg + 840 mg
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
0%200 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
66.7%120 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
33.3%80 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
100%40 mg
NCT02561455 · Phase 1/2 · registry result, not featured evidence
66.7%450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—450 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
82.4%300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—300 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
92%200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—200 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
33.3%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
78.8%120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—120 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
90.5%80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—80 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
92.3%40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—40 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
40%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
66.7%20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
—20 mg
NCT02014558 · Phase 1/2 · registry result, not featured evidence
55.1%g
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 37 more results
69.7%
NCT02039726 · Phase 3 · registry result, not featured evidence
41.2%30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
100%20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
—20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
63.9%60 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
65.8%30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence
85.4%Cohort 1; ≥60 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
76.7%Cohort 2; ≥18 Years of Age
NCT00989261 · Phase 2 · registry result, not featured evidence
20%Phase 1 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
40%Phase 2 Arm I (Quizartinib, Azacit
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
65.6%Phase 2 Arm II (Quizartinib, Cytar
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
66.7%40 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
0%20 mg/day
NCT02834390 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—60mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—40mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
—25mg/m^2/Day
NCT01411267 · Phase 1 · registry result, not featured evidence
50%ALL Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
0%ALL Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
66.7%AML Dose Level 1
NCT01411267 · Phase 1 · registry result, not featured evidence
60%AML Dose Level 2
NCT01411267 · Phase 1 · registry result, not featured evidence
40%AML Dose Level 3
NCT01411267 · Phase 1 · registry result, not featured evidence
83.3%450 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
100%300 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
75%300 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
52.9%200 mg CD
NCT00462761 · Phase 1 · registry result, not featured evidence
50%200 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
80%135 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
66.7%90 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
80%60 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
60%40 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
16.7%27 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
50%18 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
33.3%12 mg ID
NCT00462761 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
g
chronic graft versus host disease 52.8% (placebo 43.5%)
acute graft versus host disease 37.6% (placebo 36.2%)
neutrophil count decreased 27.5% (placebo 9.6%)
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 24 more results
diarrhoea 40.9%
oedema peripheral 31.8%
vomiting 31.8%
NCT02752035 · Phase 3 · monotherapy
pyrexia 42%
constipation 39.8%
diarrhoea 34.1%
NCT02752035 · Phase 3 · combination
anaemia 53.3%
diarrhoea 46.7%
neutropenia 46.7%
NCT02752035 · Phase 3 · combination
anaemia 45.5%
alanine aminotransferase increased 40.7%
aspartate aminotransferase increased 39.4%
NCT02421939 · Phase 3
blood creatine phosphokinase increased 29% (placebo 2.9%)
neutrophil count decreased 19.4% (placebo 8.6%)
platelet count decreased 19.4% (placebo 11.4%)
NCT02927262 · Phase 2 · registry result, not featured evidence
120 mg + 420 mg
decreased appetite 100%
dizziness 100%
dyspnoea 100%
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
120 mg + 840 mg
diarrhoea 50%
fatigue 50%
nausea 50%
NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination
200 mg
benign breast neoplasm 100%
cough 100%
covid-19 100%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
120 mg
cough 66.7%
decreased appetite 66.7%
diarrhoea 66.7%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
80 mg
anorectal discomfort 33.3%
anxiety 33.3%
arthralgia 33.3%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
40 mg
cough 100%
muscle spasms 100%
abdominal discomfort 50%
NCT02561455 · Phase 1/2 · registry result, not featured evidence
450 mg
aspartate aminotransferase increased 66.7%
hyperglycaemia 66.7%
abdominal pain 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
300 mg
pollakiuria 66.7%
alanine aminotransferase increased 33.3%
anaemia 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
300 mg
anaemia 35.3%
diarrhoea 29.4%
epistaxis 23.5%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
200 mg
fatigue 100%
abdominal pain 33.3%
aspartate aminotransferase increased 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
200 mg
diarrhoea 45%
aspartate aminotransferase increased 35%
anaemia 33%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
120 mg
constipation 66.7%
abdominal pain lower 33.3%
blood bilirubin increased 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
120 mg
anaemia 40.9%
diarrhoea 40.9%
fatigue 40.9%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
80 mg
decreased appetite 66.7%
nausea 66.7%
vomiting 66.7%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
80 mg
fatigue 38.1%
anaemia 33.3%
cough 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
40 mg
constipation 33.3%
dizziness 33.3%
dry skin 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
40 mg
dyspnoea 38.5%
fatigue 38.5%
anaemia 30.8%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
20 mg
anaemia 40%
nausea 40%
abdominal pain 20%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
20 mg
hypokalaemia 41.7%
fatigue 33.3%
oedema peripheral 33.3%
NCT02014558 · Phase 1/2 · registry result, not featured evidence
g
pyrexia 42.6% (placebo 39.6%)
febrile neutropenia 37% (placebo 36.2%)
diarrhoea 36.6% (placebo 35.1%)
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 30 more results
nausea 47.3%
pyrexia 36.5%
anemia 35.7%
NCT02039726 · Phase 3 · registry result, not featured evidence
30 mg/day
platelet count decreased 38.2%
electrocardiogram qt prolonged 35.3%
febrile neutropenia 29.4%
NCT02984995 · Phase 2 · registry result, not featured evidence
20 mg/day
nausea 66.7%
transfusion reaction 66.7%
anemia 33.3%
NCT02984995 · Phase 2 · registry result, not featured evidence
60 mg
nausea 47.2%
pyrexia 38.9%
diarrhea 36.1%
NCT01565668 · Phase 2 · registry result, not featured evidence
30 mg
anemia 47.4%
fatigue 34.2%
febrile neutropenia 31.6%
NCT01565668 · Phase 2 · registry result, not featured evidence
nausea 54.1%
diarrhea 41.4%
fatigue 39.5%
NCT00989261 · Phase 2 · registry result, not featured evidence
nausea 50.6%
vomiting 39.8%
diarrhea 38.1%
NCT00989261 · Phase 2 · registry result, not featured evidence
alanine aminotransferase increased 80%
blood bilirubin increased 80%
hypocalcemia 80%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
alanine aminotransferase increased 100%
allergic rhinitis 100%
anemia 100%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
hypomagnesemia 65.7%
creatinine decreased 62.9%
hypokalemia 62.9%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
pain 50%
nausea 43.8%
diarrhea 40.6%
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination
40 mg/day
electrocardiogram qt prolonged 100%
febrile neutropenia 100%
alopecia 66.7%
NCT02834390 · Phase 1 · registry result, not featured evidence
20 mg/day
febrile neutropenia 100%
abdominal pain upper 75%
alopecia 75%
NCT02834390 · Phase 1 · registry result, not featured evidence
platelet count decreased 100%
anemia 50%
ara-c skin rash 50%
NCT01411267 · Phase 1 · registry result, not featured evidence
hypokalemia 100%
anemia 50%
arthralgia 50%
NCT01411267 · Phase 1 · registry result, not featured evidence
anemia 100%
white blood cell decreased 100%
alanine aminotransferase increased 66.7%
NCT01411267 · Phase 1 · registry result, not featured evidence
white blood cell decreased 100%
anemia 80%
febrile neutropenia 60%
NCT01411267 · Phase 1 · registry result, not featured evidence
hypokalemia 90%
hypomagnesemia 80%
platelet count decreased 70%
NCT01411267 · Phase 1 · registry result, not featured evidence
450 mg ID
asthenia 66.7%
diarrhoea 66.7%
disease progression 66.7%
NCT00462761 · Phase 1 · registry result, not featured evidence
300 mg CD
ecg qt prolonged 50%
anaemia 37.5%
cough 37.5%
NCT00462761 · Phase 1 · registry result, not featured evidence
300 mg ID
anaemia 50%
dyspnoea 50%
fatigue 50%
NCT00462761 · Phase 1 · registry result, not featured evidence
200 mg CD
pyrexia 41.2%
vomiting 41.2%
epistaxis 35.3%
NCT00462761 · Phase 1 · registry result, not featured evidence
200 mg ID
nausea 83.3%
chills 50%
diarrhoea 50%
NCT00462761 · Phase 1 · registry result, not featured evidence
135 mg ID
fatigue 60%
febrile neutropenia 60%
nausea 40%
NCT00462761 · Phase 1 · registry result, not featured evidence
90 mg ID
febrile neutropenia 100%
headache 66.7%
nausea 66.7%
NCT00462761 · Phase 1 · registry result, not featured evidence
60 mg ID
disease progression 80%
anaemia 60%
nausea 60%
NCT00462761 · Phase 1 · registry result, not featured evidence
40 mg ID
pyrexia 60%
anaemia 40%
cough 40%
NCT00462761 · Phase 1 · registry result, not featured evidence
27 mg ID
nausea 50%
anaemia 33.3%
fatigue 33.3%
NCT00462761 · Phase 1 · registry result, not featured evidence
18 mg ID
diarrhoea 37.5%
dizziness 37.5%
hypokalaemia 37.5%
NCT00462761 · Phase 1 · registry result, not featured evidence
12 mg ID
abdominal pain 66.7%
cough 66.7%
asthenia 33.3%
NCT00462761 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 1/2 versus Phase 2.
  3. cPopulation context differs: registered conditions differ.
  4. dTreatment context has not been resolved for both arms.
  5. eThe assessment timepoint is not available for both results.
  6. fPopulation comparability has not been reviewed for both studies.
  7. gPopulation comparability has not been reviewed for 37 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Gilteritinib

Relapse-free Survival NA vs NA placebo months
time to event · months
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
show 1 more result
24.02 vs 15.84 placebo months
NCT02927262 · Phase 2 · registry result, not featured evidence
Non-Relapse Mortality 13.6% (n=178) vs 6.6% (n=178) placebo
responder rate · % of participants
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
Relapse 12.4% (n=178) vs 26.7% (n=178) placebo
responder rate · % of participants
NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3
Complete Remission With Incomplete Platelet Recovery 6.7% (n=89) vs 0% (n=57) AZA
responder rate · % of participants
CRp
NCT02752035 · Phase 3 · combination
show 1 more result
18.2% (n=22) vs 0% (n=57) AZA
CRp
NCT02752035 · Phase 3 · monotherapy
Complete Remission With Incomplete Recovery 29.2% (n=89) vs 10.5% (n=57) AZA
responder rate · % of participants
CRi
NCT02752035 · Phase 3 · combination
show 1 more result
27.3% (n=22) vs 10.5% (n=57) AZA
CRi
NCT02752035 · Phase 3 · monotherapy
Complete Remission 25.8% (n=89) vs 17.5% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 2 more results
9.1% (n=22) vs 17.5% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
21.1% (n=247) vs 10.5% (n=124) Salvage Chemotherapy @ 24wk
NCT02421939 · Phase 3
CRc 61.8% (n=89) vs 28.1% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
54.5% (n=22) vs 28.1% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
CRh 10.1% (n=89) vs 1.8% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
22.7% (n=22) vs 1.8% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
CR or CRh 36% (n=89) vs 19.3% (n=57) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
31.8% (n=22) vs 19.3% (n=57) AZA
NCT02752035 · Phase 3 · monotherapy
Transfusion Conversion 35.6% (n=73) vs 44.7% (n=38) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
61.1% (n=18) vs 44.7% (n=38) AZA
NCT02752035 · Phase 3 · monotherapy
Transfusion Maintenance 100% (n=3) vs 50% (n=2) AZA
responder rate · % of participants
NCT02752035 · Phase 3 · combination
show 1 more result
50% (n=2) vs 50% (n=2) AZA
NCT02752035 · Phase 3 · monotherapy
LFS 7.16 vs 8.08 AZA months
absolute value · months
NCT02752035 · Phase 3 · combination
show 2 more results
3.2 vs 8.08 AZA months
NCT02752035 · Phase 3 · monotherapy
4.4 vs 6.7 Salvage Chemotherapy months
NCT02421939 · Phase 3

+ 27 further endpoints in the CSV export.

Quizartinib

Clinical Remission 54.9% (n=268) vs 55.4% (n=271) placebo
responder rate · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 147 Participants as posted
Composite Clinical Remission 71.6% (n=268) vs 64.9% (n=271) placebo
responder rate · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 192 Participants as posted
CR MRD Negative 20.1% (n=268) vs 18.8% (n=271) placebo
event count · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 54 Participants as posted
Composite CR MRD Negative 24.6% (n=268) vs 21.4% (n=271) placebo
event count · % of participants
Induction
NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 · converted to % from 66 Participants as posted
Overall 79.2% (n=24)30 mg/day
responder rate · % of participants
No placebo or comparator arm
NCT02984995 · Phase 2 · registry result, not featured evidence
show 5 more results
66.7% (n=3)20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
40% (n=5) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
100% (n=1) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
77.1% (n=35) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 27 Participants as posted
59.4% (n=32) @ 8wk*
NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination · converted to % from 19 Participants as posted
Duration of Complete Response 3.72 months30 mg/day
time to event · months
No placebo or comparator arm
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 16.1 weeks as posted
show 5 more results
NA months20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
2.79 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 12.1 weeks as posted
2.45 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 10.6 weeks as posted
3.78 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 16.4 weeks as posted
1.62 months*
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 7 weeks as posted
LFS 2.1 months @ 156wk60 mg
absolute value · months
No placebo or comparator arm
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 9.1 weeks as posted
show 3 more results
3.72 months*30 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 16.1 weeks as posted
0.95 months @ 156wk*30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 4.1 weeks as posted
NA months20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
Hematopoietic Stem Cell Transplantation 37.9% (n=29)30 mg/day
responder rate · % of participants
No placebo or comparator arm
NCT02984995 · Phase 2 · registry result, not featured evidence
show 1 more result
33.3% (n=3)20 mg/day
NCT02984995 · Phase 2 · registry result, not featured evidence
Composite Complete 47.4% (n=38) @ 8wk60 mg
responder rate · % of participants
No placebo or comparator arm
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
show 1 more result
47.4% (n=38) @ 8wk*30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to % from 18 Participants as posted
Time to Response 1.06 months @ 156wk60 mg
time to event · months
No placebo or comparator arm
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 4.6 weeks as posted
show 1 more result
1.02 months @ 156wk*30 mg
NCT01565668 · Phase 2 · registry result, not featured evidence · converted to months from 4.4 weeks as posted
Complete Remission 0% (n=3)40 mg/day
responder rate · % of participants
No placebo or comparator arm
Complete remission (CR)
NCT02834390 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 5 more results
0% (n=4)*20 mg/day
Complete remission (CR)
NCT02834390 · Phase 1 · registry result, not featured evidence · converted to % from 0 Participants as posted
2.7% (n=112) @ 12wk*
Complete remission (CR)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 3 participants as posted
3.7% (n=136) @ 12wk*
Complete remission (CR)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 5 participants as posted
4.5% (n=44) @ 12wk*
Complete remission (CR)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 2 participants as posted
2.5% (n=40) @ 12wk*
Complete remission (CR)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted
Complete Remission With Incomplete Platelet Recovery 3.6% (n=112) @ 12wk
responder rate · % of participants
No placebo or comparator arm
Complete remission with incomplete platelet (CRp)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 4 participants as posted
show 3 more results
1.5% (n=136) @ 12wk*
Complete remission with incomplete platelet (CRp)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 2 participants as posted
2.3% (n=44) @ 12wk*
Complete remission with incomplete platelet (CRp)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted
2.5% (n=40) @ 12wk*
Complete remission with incomplete platelet (CRp)
NCT00989261 · Phase 2 · registry result, not featured evidence · converted to % from 1 participants as posted

+ 13 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gilteritinib's landscape · Quizartinib's landscape